Insider · CIK 0001652901
Avalon Ventures XI, L.P.
owner
Files at JANX (Janux Therapeutics, Inc.). First filing Oct 18, 2024, latest Oct 18, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $77M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JANX: Janux Therapeutics, Inc.
JANXOct 9, 2026 · close 18.39
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Janux Therapeutics, Inc. | $77M 1,673,128 shares | -59% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -60,179 | $49.69 | $3.0M | 2,761,291 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -11,657 | $49.69 | $579k | 534,883 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, L.P. | -61,445 | $49.69 | $3.1M | 2,819,366 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -29,474 | $50.61 | $1.5M | 2,731,817 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -5,710 | $50.61 | $289k | 529,173 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, LP | -30,094 | $50.61 | $1.5M | 2,789,272 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +4,968 | $17.00 | $84k | 11,855 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +2,070 | $10.73 | $22k | 13,925 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +2,070 | $13.22 | $27k | 15,995 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +1,407 | $39.80 | $56k | 17,402 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -10,957 | $50.80 | $557k | 6,445 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +836 | $17.00 | $14k | 7,281 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +348 | $10.73 | $3,734 | 7,629 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +348 | $13.22 | $4,601 | 7,977 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Common Stock | +237 | $39.80 | $9,433 | 8,214 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -1,843 | $50.02 | $92k | 6,371 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -102,732 | $50.30 | $5.2M | 2,629,085 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -19,900 | $50.30 | $1.0M | 509,273 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, L.P. | -104,892 | $50.30 | $5.3M | 2,684,380 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -15,462 | $51.18 | $791k | 2,613,623 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -2,995 | $51.18 | $153k | 506,278 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, L.P. | -15,788 | $51.18 | $808k | 2,668,592 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stock | -541,824 | $44.75 | $24M | 2,071,799 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures I, LP | -104,957 | $44.75 | $4.7M | 401,321 | Oct 18, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Avalon BioVentures SPV I, L.P. | -553,219 | $44.75 | $25M | 2,115,373 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -4,968 | $0.00 | $0 | 22,776 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -2,070 | $0.00 | $0 | 9,490 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -2,070 | $0.00 | $0 | 9,490 | Oct 18, 2024 |
| Oct 16, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -1,407 | $0.00 | $0 | 6,309 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -836 | $0.00 | $0 | 21,940 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -348 | $0.00 | $0 | 9,142 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -348 | $0.00 | $0 | 9,142 | Oct 18, 2024 |
| Oct 17, 2024 | JANX Janux Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -237 | $0.00 | $0 | 6,072 | Oct 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.